Figure 3: Blood glucose levels over the time course
A display of the patient‘s highest (red) and lowest (blue) blood glucose
levels for each day of her hospital stay, along with the concurrent
Octreotide (grey) and glucose therapy (orange). Octreotide was paused on
day 17 because of a DOTA-TATE-PET/CT-scan on day 18. The combination of
800 μg Octreotide per day and continuous intravenous glucose infusions
maintained adequate blood glucose levels above 50 mg/dl. However, blood
glucose levels were highly variable. Immediately after redebulking
surgery on day 23, they stabilized at appropriate levels.